Explore the words cloud of the TransPot project. It provides you a very rough idea of what is the project "TransPot" about.
The following table provides information about the project.
UNIVERSITY OF GLASGOW
|Coordinator Country||United Kingdom [UK]|
|Total cost||2˙629˙315 €|
|EC max contribution||2˙629˙315 € (100%)|
1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
|Duration (year-month-day)||from 2017-01-01 to 2020-12-31|
Take a look of project's partnership.
|1||UNIVERSITY OF GLASGOW||UK (GLASGOW)||coordinator||273˙287.00|
|2||GenomeScan B.V.||NL (Leiden)||participant||319˙217.00|
|3||ALMAC DIAGNOSTIC SERVICES LIMITED||UK (CRAIGAVON)||participant||273˙287.00|
|4||UNIVERSITY OF NEWCASTLE UPON TYNE||UK (NEWCASTLE UPON TYNE)||participant||273˙287.00|
|5||TAMPEREEN KORKEAKOULUSAATIO SR||FI (TAMPERE)||participant||269˙145.00|
|6||TURUN YLIOPISTO||FI (Turku)||participant||269˙145.00|
|7||ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM||NL (ROTTERDAM)||participant||255˙374.00|
|8||NUMARES AG||DE (REGENSBURG)||participant||249˙216.00|
|9||IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON||EL (ATHINA)||participant||242˙386.00|
|10||THE QUEEN'S UNIVERSITY OF BELFAST||UK (BELFAST)||participant||204˙965.00|
|11||MOSAIQUES DIAGNOSTICS GMBH||DE (HANNOVER)||participant||0.00|
|12||TAMPEREEN YLIOPISTO||FI (TAMPERE)||participant||0.00|
|13||CANCER RESEARCH UK LBG||UK (LONDON)||partner||0.00|
|14||Carver Wilde Communications||UK (London)||partner||0.00|
|15||European Association of Urology||CH (Bern)||partner||0.00|
|16||HELSINGIN YLIOPISTO||FI (HELSINGIN YLIOPISTO)||partner||0.00|
|17||Prostate Cancer UK||UK (London)||partner||0.00|
|18||UNIVERSITY OF STRATHCLYDE||UK (GLASGOW)||partner||0.00|
The Translational Research Network for Prostate Cancer (TransPot) program adopts an innovative, multidisciplinary approach, providing highly sought-after, effective solutions for incurable prostate cancer (PC).
The TransPot scientific objective is to obtain an unmatched depth of molecular, mechanistic and informatics systems-level disease understanding in order to improve the prognosis and treatment of lethal PC, aimed to (i) provide important insights into molecular mechanisms driving treatment resistant PC including castrate-resistant PC (CRPC), (ii) identify novel therapeutic targets, (iii) develop and validate predictive models for disease progression, prognosis and responsiveness to current and novel (co-)treatment options, and (iv) provide superior, clinically relevant tools and biomarker signatures for personalising and optimising CRPC therapy. Our research program is built on network-wide, state-of-the-art cancer biology-based mechanistic research integrated with a systems medicine approach: 1. Cancer biology-based mechanistic research incorporating a comprehensive range of model systems incorporating unique, pre-clinical and clinical resources and distinct phenotypic high content screen platforms. 2. A systems medicine approach with mathematical modelling to develop novel predictive/prognostic tools. 3. Centres of excellence in surgery, oncology and clinical trials, comprising clinical infrastructure and essential resources whereby candidate therapeutic targets and predictive/prognostic tools can be comprehensively evaluated, including accessing bio-repository resources. We will train young scientists to apply multiple ‘omics’ technologies and approaches in model systems and systems biology to answer important clinically-relevant questions. Advances achieved will facilitate personalized targeted-medicine in treating lethal PC, and will impact beyond the scientific community by improving the well-being of advanced PC patients.
|ESRs Recruitment||Other||2020-04-15 09:09:56|
|TransPot website and social media presence built, maintained and operated||Websites, patent fillings, videos etc.||2020-04-15 09:09:56|
|PCDP and researcher declarations||Other||2020-04-15 09:09:56|
Take a look to the deliverables list in detail: detailed list of TransPot deliverables.
|year||authors and title||journal||last update|
Marouane Kdadra, Sebastian HÃ¶ckner, Hing Leung, Werner Kremer, Eric Schiffer
Metabolomics Biomarkers of Prostate Cancer: A Systematic Review
published pages: 21, ISSN: 2075-4418, DOI: 10.3390/diagnostics9010021
S. Umbreen, R.E. Steele, N. Poulose, S. Mcdade, N. Mccabe, I.G. Mills
Approaches to enrich for androgen receptor binding sites in low-cell number samples
published pages: e2499, ISSN: 1569-9056, DOI: 10.1016/s1569-9056(18)32982-8
|European Urology Supplements 17/10||2020-04-15|
P. Singh, C.N. Robson, R. Heer
In vitro prostate differentiation of induced pluripotent stem cells and organoid generation using seminal vesicle mesenchyme
published pages: e2557, ISSN: 1569-9056, DOI: 10.1016/s1569-9056(18)33034-3
|European Urology Supplements 17/10||2020-04-15|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRANSPOT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "TRANSPOT" are provided by the European Opendata Portal: CORDIS opendata.